Clinical Trials
64 trialsDUET-MEL
Beijing Biotech
A Registry of Subjects With Primary Indeterminate Lesions or Choroidal Melanoma
Aura Biosciences
ACTengine
Immatics US, Inc.
Safety and Preliminary Efficacy of MBS8(1V270) in Cancer Patients With Advanced Solid Tumours
MonTa Biosciences ApS
Neoadjuvant Darovasertib in Primary Uveal Melanoma
IDEAYA Biosciences
Targeted Alpha Particle Radiotherapy for Metastatic Uveal Melanoma
Modulation Therapeutics, Inc.
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
Replimune, Inc.
A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers
iOnctura
Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma
Immunocore Ltd
(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma
IDEAYA Biosciences
A Phase 1-1b Study to Evaluate the Safety, Efficacy and Dosimetry of Study Drug A9-3408 in Subjects With Metastatic Melanoma
Alpha-9 Oncology USA Inc.
A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Endeavor Biomedicines, Inc.
CoMpass
Aura Biosciences
Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors
Replimune, Inc.
Choroidal Melanoma Patient-Reported Outcome Study (CM-PRO) in a Subset of AU-011-301 (CoMpass) Subjects
Aura Biosciences
IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma
IDEAYA Biosciences
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
IDEAYA Biosciences
OCULE-01
iOnctura
CoMpass
Aura Biosciences
A Phase 1 Study of [225Ac]-FPI-1434 Injection
Fusion Pharmaceuticals Inc.
ON-5001
OncoNano Medicine, Inc.
KZR-261 in Subjects With Advanced Solid Malignancies
Kezar Life Sciences, Inc.
Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab
Linnaeus Therapeutics, Inc.
A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel
Iovance Biotherapeutics, Inc.
NBM-BMX-UM
Novelwise Pharmaceutical Corporation
Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma
BioInvent International AB
A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors
TScan Therapeutics, Inc.
Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma
TriSalus Life Sciences, Inc.
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
Novelty Nobility, Inc.
A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors
Ascentage Pharma Group Inc.
A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas
Novartis
A Study of SEA-CD40 Given With Other Drugs in Cancers
Seagen Inc.
STARLING
Turnstone Biologics, Corp.
Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma
Aura Biosciences
FHD-286 in Subjects With Metastatic Uveal Melanoma
Foghorn Therapeutics Inc.
Study in Subjects With Small Primary Choroidal Melanoma
Aura Biosciences
FOCUS
Delcath Systems Inc.
An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma
Delcath Systems Inc.
TIMAR1
Perspective Therapeutics
Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma
Bellicum Pharmaceuticals
IL
Aura Biosciences
CLEVER
Viralytics
A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma
Immunocore Ltd
A Study to Assess PV-10 Chemoablation of Cancer of the Liver
Provectus Pharmaceuticals
A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas
Hoffmann-La Roche
A Phase I Study of LXS196 in Patients With Metastatic Uveal Melanoma.
Novartis
A Study of PLX2853 in Advanced Malignancies.
Opna Bio LLC
CLEAR
Castle Biosciences Incorporated
Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566
Pfizer
Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma
Bristol-Myers Squibb